Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Northwest Biotherapeutics is a biotechnology company specializing in personalized immune therapies for cancer. Its platform, DCVax, uses a patient’s own dendritic cells to target solid tumors, with products like DCVax-L for surgically removable cancers and DCVax-Direct for inoperable tumors. The company focuses on immunotherapy development, manufacturing, and regulatory approval, primarily serving cancer patients worldwide. It emphasizes innovation, patent protection, and strategic collaborations in the competitive cancer treatment market.
This description was generated via AI from an annual report. Updated about 1 year ago.